Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 28, 2026 | Aug 4, 2026 | −$0.04 | −107.8% | $15.03B | +2.6% | $0.68 |
| Q1 FY26ended Mar 29, 2026 | May 5, 2026 | $0.47 | −9.6% | $14.45B | +5.4% | $0.71 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.29 | −514.3% | $17.56B | −1.2% | — |
| Q3 FY25ended Sep 28, 2025 | — | $0.62 | −20.5% | $16.65B | −5.9% | — |
| Q2 FY25ended Jun 29, 2025 | — | $0.51 | +5000.0% | $14.65B | +10.3% | — |
| Q1 FY25ended Mar 30, 2025 | — | $0.52 | −5.5% | $13.72B | −7.8% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.07 | — | $17.76B | +21.9% | — |
| Q3 FY24ended Sep 29, 2024 | — | $0.78 | — | $17.70B | +31.2% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Pfizer shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.01 | — | $13.28B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.55 | — | $14.88B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.59 | — | $14.57B | — | — |
| Q3 FY23ended Oct 1, 2023 | — | −$0.42 | — | $13.49B | — | — |